Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.5352W HIGH $5.36
Volume
386.00
Value Traded
896.55
Short % Float
0%
-2.81%Week
-8.85%1 Month
-4.99%3 Month
-9.5%6 Month
-79.1%5 Year
-79.1%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
153.83 M
EPS (TTM)
-1.93
P/E Ratio
-
Ent. Value
68.10 M
Total Shares
40.37 M
Float Shares
38.20 M
Insiders
0.28%
Institutions
9.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MOLN Catalyst Timeline
Dated clinical, regulatory and corporate events for Molecular Partners AG
Catalyst Timeline
Dated clinical, regulatory & corporate events for Molecular Partners AG
364Total events
10Upcoming
72Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Dose Finding UpdateMP0712Trial
MP0712 advancing to higher dose level in Phase 1/2a study
small cell lung cancersource ↗
●Poster PresentationMP0712Presentation
Poster presentation at SNMMI 2026
small cell lung cancer and other DLL3-expressing solid tumorssource ↗
●Poster PresentationMP0712Presentation
Trial-in-progress poster presentation at ASCO 2026
small cell lung cancer and other DLL3-expressing solid tumorssource ↗
▲First Patient DosedMP0712Trial
First patient dosed in Phase 1/2a study of MP0712
small cell lung cancer and other neuroendocrine cancerssource ↗
◆Oral PresentationMP0712Presentation
Oral presentation at Antibody & Engineering Therapeutics on MP0712
small cell lung cancer (SCLC)source ↗
◆Oral PresentationPresentation
Fireside chat at TD Cowen's 7th Annual Oncology Innovation Summit
◆Oral PresentationMP0712Presentation
Oral presentation at 22nd Annual PEGS Boston on MP0712
small cell lung cancer (SCLC)source ↗
▲Trial InitiationMP0712Trial
Phase 1/2a study of MP0712 started
small cell lung cancer and other neuroendocrine cancerssource ↗
▲Trial InitiationMP0317Trial
Investigator-initiated Phase 2 study of MP0317 started
advanced cholangiocarcinomasource ↗
●Enrollment UpdateMP0317Trial
Eight sites activated for MP0317 Phase 2 study
advanced cholangiocarcinomasource ↗
▲Enrollment CompleteMP0533Trial
Dose escalation part fully recruited (10 cohorts)
relapsed/refractory AML and MDS/AMLsource ↗
▼Runway Guidance UpdateCorporate
Cash runway guidance updated to late 2027 (previously early 2028)
◆Oral PresentationMP0712Presentation
Oral presentation at NIH NCI 2026 SCLC Consortium Meeting on MP0712
small cell lung cancer (SCLC)source ↗
▲Full ResultsMP0317Clinical Data
Phase 1 MP0317 data published in Nature Cancer demonstrating tumor-localized CD40 activation and TME remodeling
advanced solid tumorssource ↗
▲Trial InitiationMP0317Trial
Randomized Phase 2 investigator-initiated trial of MP0317 in front-line cholangiocarcinoma open with patient dosing ongoing
front-line cholangiocarcinomasource ↗
●Enrollment UpdateMP0317Trial
Patient dosing ongoing in Phase 2 cholangiocarcinoma trial
front-line cholangiocarcinomasource ↗
▲PublicationMP0317Presentation
Phase 1 results published in Nature Cancer (e-pub 1 May 2026)
advanced solid tumorssource ↗
◆Poster PresentationMP0712Presentation
Poster presentation on MP0712 molecular characteristics at AACR 2026
Small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancerssource ↗
◆Poster PresentationPresentation
Poster presentation on computational workflow for tumor-antigen profiling at AACR 2026
Cancer (immunotherapy platform)source ↗
◆Poster PresentationMP0632Presentation
Poster presentation on MP0632 preclinical data at AACR 2026
MSLN/EpCAM expressing solid tumors (ovarian cancer)source ↗
●Development Candidate NominationMP0632Preclinical
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate
MSLN/EpCAM expressing solid tumors (ovarian cancer)source ↗
●Quarterly UpdateCorporate
Annual General Meeting approved all board proposals and financial statements
▲Preclinical PoCMP0632Preclinical
Preclinical data presented at AACR April 2026 supporting Switch-DARPin proof-of-concept
solid cancers expressing MSLN and EpCAMsource ↗
●Development Candidate NominationPreclinical
Nomination of new Radio-DARPin candidates anticipated
◆Oral PresentationPresentation
Oral presentation at 3rd Global Radiopharmaceuticals Development Summit
▲Trial InitiationMP0712Trial
US Phase 1/2a study of MP0712 initiated
small cell lung cancer and other neuroendocrine cancerssource ↗
▲Trial InitiationMP0317Trial
Phase 2 investigator-initiated randomized trial of MP0317 combined with standard-of-care for cholangiocarcinoma opened
advanced cholangiocarcinomasource ↗
●Enrollment UpdateMP0317Trial
Patient dosing ongoing in MP0317 Phase 2 study
advanced cholangiocarcinomasource ↗
◆Oral PresentationPresentation
Leerink Partners Global Healthcare Conference 2026 fireside chat
●Preclinical PoCPreclinical
Pre-clinical data on Radio-DARPins with multiple isotopes to be presented
●Oral PresentationPresentation
Pre-clinical data on Radio-DARPins suitability with multiple isotopes at 3rd Global Radiopharmaceuticals Development Summit
▲Partnership / LicenseCorporate
Development agreement with Eckert & Ziegler for Radio-DARPin therapeutics
▲Trial InitiationMP0712Trial
Phase 1/2a trial for MP0712 targeting DLL3 opened
small cell lung cancer (SCLC)source ↗
▲Partnership / LicenseCorporate
Agreement with Eckert & Ziegler for development and manufacturing of Radio-DARPin therapeutics
▲Oral PresentationMP0712Presentation
Oral presentation of first imaging and dosimetry data of MP0712 at TWC 2026
small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancerssource ↗
▲Poster PresentationMP0712Presentation
Poster presentations of MP0712 imaging and dosimetry data at TWC 2026
small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancerssource ↗
▲Trial InitiationMP0712Trial
Phase 1/2a trial of MP0712 started
small cell lung cancer (SCLC) and other neuroendocrine cancerssource ↗
▲Trial InitiationMP0317Trial
Phase 2 investigator-initiated trial of MP0317 open with patient dosing ongoing
advanced cholangiocarcinomasource ↗
▲Oral PresentationMP0712Presentation
First patient imaging and dosimetry data presented at TWC January 2026
small cell lung cancer and other DLL3-expressing tumorssource ↗
▲Trial InitiationMP0712Trial
U.S. Phase 1/2a study of MP0712 ongoing
small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancerssource ↗
◆Full ResultsMP0712Clinical Data
Full imaging and dosimetry data of MP0712 to be reported at Theranostics World Congress
small cell lung cancer (SCLC) and other neuroendocrine cancerssource ↗
▲First Patient DosedMP0712Trial
First patient dosing expected for MP0712
small cell lung cancer (SCLC) and other neuroendocrine cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How MOLN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | MP0712 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$75M
Pipeline Value
Overvalued
Valuation Signal
6
Drugs Scored
0.5x
rNPV / MCap
Top 55%
Micro Cap(rank 362 of 658)
Percentile Rank
Molecular Partners AG faces pipeline headwinds (35/100), with $865M risk-adjusted pipeline value, led by ensovibep in Covid19 (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ensovibep Small moleculeCompletedNCT04834856 | Covid19 | Phase 2 | COMPLETED | 12 | Aug 20, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every MOLN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MP0317 | advanced solid tumors | Phase 1 | 2026-05-01 | total patients: 46; unconfirmed partial response: 1; stable disease: 14Read More | Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodelingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MOLN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.1 % (-50 %) | 5.14 M | 1.35 M |
MOLN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MOLN ranks across every disease it competes in
Competitive Position is a premium feature
See how MOLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMOLN News
MOLNMolecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
Molecular Partners has reported its H1 2026 financial results, highlighting the progress of DLL3-targeting Radio-DARPin MP0712, which is now recruiting at dose level 2 in its Phase 1/2a trial. Initial data is anticipated in 2026, with efficacy results expected in 2027. Additionally, CD70 has been selected as a new radio target for kidney cancer treatment.
Read more →MOLNMolecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
Molecular Partners is making significant progress in its Phase 2 TACTIC trial for MP0317, targeting cholangiocarcinoma. The study is currently active with nine sites recruiting patients. An update on the trial data is expected in 2027, with completion projected for 2028. A trial-in-progress poster will be presented at ESMO 2026.
Read more →MOLNMolecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
Molecular Partners presented its bispecific Radio-DARPins at the Gordon Research Conference, highlighting their potential to engage multiple tumor targets at once. This innovative approach aims to enhance precision and therapeutic efficacy in cancer treatment. The presentation emphasized the technology's ability to align with target and disease biology for improved patient outcomes.
Read more →MOLNMolecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
Molecular Partners has provided an update on its Phase 1/2a trial of MP0712, a DLL3-targeted Radio-DARPin co-developed with Orano Med. Dosing is currently ongoing in the first patients, with initial data expected in the coming months. Comprehensive efficacy data is projected to be available by 2027, indicating significant future insights into the treatment's effectiveness.
Read more →MOLNMolecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
Molecular Partners and Orano Med have initiated a Phase 1/2a trial for DLL3-targeting Radio-DARPin MP0712, with the first patients dosed. The trial is being conducted at five sites in the US, and initial data is anticipated in the coming months, while comprehensive efficacy data is expected by 2027.
Read more →MOLN▼ -6%on this news
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Molecular Partners announced presentations at ASCO and SNMMI 2026 regarding its Phase 1/2a study of MP0712, a targeted alpha radiotherapy candidate for small cell lung cancer. The study is currently dosing patients and aims to assess safety and determine a recommended Phase 2 dose. Initial clinical data is anticipated later in 2026.
Read more →MOLNMolecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Molecular Partners AG, a clinical-stage biotech firm specializing in DARPin therapeutics, will present at TD Cowen's 7th Annual Oncology Innovation Summit on May 27, 2026. The management team will participate in a fireside chat at the event, which will be webcasted for broader access. This participation highlights the company's efforts to showcase their innovative approaches in overcoming treatment challenges in cancer.
Read more →MOLNMolecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
Molecular Partners AG reported strong financial results and clinical advancements for Q1 2026, highlighting the initiation of clinical studies for its lead programs, MP0712 and MP0317. The company emphasized a solid financial runway with 79 million CHF in cash and the successful opening of multiple trial sites. Initial clinical data for MP0712, targeting small cell lung cancer, is expected within the year. Additionally, new approaches in isotopes for the Radio-DARPin therapy aim to enhance treatment strategies across various cancers.
Read more →MOLNMolecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Molecular Partners AG announced its participation in several upcoming scientific conferences to present its lead Radio-DARPin candidate MP0712. The presentations will focus on the drug's molecular characteristics and its development for targeted anti-DLL3 radiotherapy in small cell lung cancer. These events are significant for showcasing advancements in their therapeutic approach.
Read more →MOLNMolecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
Molecular Partners has published positive Phase 1 data for MP0317, demonstrating its ability to activate CD40 specifically within the tumor microenvironment, which could lead to improved efficacy and reduced side effects compared to traditional therapies. The study showed a favorable safety profile and evidence of tumor microenvironment remodeling. A Phase 2 trial for cholangiocarcinoma is currently underway.
Read more →MOLNMolecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
Molecular Partners AG has presented new preclinical data at the AACR Annual Meeting 2026, showcasing the Switch-DARPin T cell engager MP0632 aimed at treating MSLN and EpCAM expressing tumors. Additionally, the company introduced MP0712, a Radio-DARPin candidate currently in a Phase 1/2a trial for small cell lung cancer. The data highlights MP0632's potential for selective tumor cell targeting with minimal impact on non-targeted cells, and a novel computational workflow aiding in the discovery of tumor-associated antigens. The findings suggest significant advances in cancer immunotherapy and targeted therapies.
Read more →MOLNMolecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
Molecular Partners AG announced the election of Clare Fisher to its Board of Directors during the Annual General Meeting. Shareholders approved all proposals put forth by the Board, showing significant backing for its direction. Fisher brings over two decades of experience in the pharmaceutical industry, particularly in corporate development and strategy. Additionally, the AGM confirmed the financial results for 2025 and re-elected current board members while providing discharge for the previous financial year. This move signals a commitment to strong governance and strategic growth.
Read more →MOLNMolecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
Molecular Partners has announced the invitation to its Annual General Meeting scheduled for April 14, 2026, where Clare Fisher is nominated for election to the Board of Directors. Fisher brings over two decades of experience in biotech and corporate development. Current board member Steven H. Holtzman will not seek re-election after 12 years of service.
Read more →MOLNMolecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
Molecular Partners AG presented new preclinical data on Radio-DARPins that demonstrate their suitability for multiple isotopes at the 3rd Global Radiopharmaceuticals Development Summit. The data indicate comparable biodistribution profiles for two candidates labeled with Lutetium-177 and Lead-203, suggesting potential efficacy in tumor targeting. The company's innovative approach allows for the selection of therapeutic isotopes late in the drug development process, which could streamline treatments tailored to patient needs. Moreover, the partnership with Eckert & Ziegler is expected to bolster the development of these novel therapeutics.
Read more →MOLNMolecular Partners to Hold Three Poster Presentations at AACR 2026
Molecular Partners AG, a clinical-stage biotech company, announced that it will hold three poster presentations at the AACR 2026 Annual Meeting in San Diego. The presentations will cover topics including an innovative T cell engager designed for improved safety in cancer therapy and a study on the molecular characteristics of a new Radio-DARPin candidate targeting small cell lung cancer. The company's focus on advancing DARPin therapeutics highlights its ongoing commitment to develop novel cancer treatment strategies.
Read more →MOLNMolecular Partners Reports Highlights and Financial Results for Full Year 2025
Molecular Partners AG announced significant advancements in its drug development pipeline and financial standing for the full year 2025. The company has initiated a Phase 1/2a clinical trial for its Radio-DARPin candidate MP0712, targeting DLL3 for small cell lung cancer. Financially, they report a strong position with CHF 93.1 million in cash, securing operations until 2028. Additionally, developments in other Radio-DARPin candidates and strategic partnerships were also highlighted, setting the stage for future growth.
Read more →MOLNMolecular Diagnostics Market Outlook: Set to Grow at 10%+ CAGR Through 2031 as Precision Medicine and Genetic Testing Advance, Says Mordor Intelligence
The molecular diagnostics market is set to grow significantly, with projections reaching $33.51 billion by 2031 at a CAGR of 10.43%. This growth is driven by a rise in the prevalence of infectious and chronic diseases, coupled with advancements in genomic and molecular testing technologies. As healthcare systems increasingly prioritize precision medicine, the demand for molecular diagnostics continues to strengthen. Key regions contributing to this market growth include North America, Europe, and the Asia-Pacific, supported by innovations and investments in healthcare infrastructure.
Read more →MOLNMolecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
Molecular Partners AG has announced its participation in upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The company's CEO will take part in fireside chats during these events. Additionally, Molecular Partners will release its full-year 2025 financial report on March 12, 2026.
Read more →MOLNMolecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
Molecular Partners has signed a development agreement with Eckert & Ziegler to advance Radio-DARPin therapeutics, which utilize alpha-emitting isotopes for targeted cancer treatment. This partnership aims to enhance the development and manufacturing processes for these innovative therapies. The agreement will leverage Eckert & Ziegler's expertise and facilities, including a dedicated Alpha Laboratory in Berlin.
Read more →MOLN▲ +7.5%on this news
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
Molecular Partners presented promising imaging and dosimetry data for MP0712, a DLL3-targeted radiotherapy, at the Theranostics World Congress 2026. The data, derived from five patients, indicate favorable tumor uptake and minimal healthy tissue accumulation. This supports the ongoing Phase 1/2a study aimed at assessing the safety and efficacy of MP0712 in treating small cell lung cancer and other neuroendocrine cancers.
Read more →About Molecular Partners AG
BIOPHARMAWATCH ELITE PLUS
Trade the next MOLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime